Celyad Completes $100 Million IPO

Boston – July 27, 2015 – Cooley advised the underwriters on Celyad SA's initial public offering of American Depositary Shares (ADSs) and concurrent private placement in Europe. Celyad, based in Belgium, is a clinical-stage specialty biopharmaceutical company focused on changing the fields of cardiology and oncology by developing novel cell therapy treatment platforms called C-Cure and CAR-NKG2D. The company's ADSs trade on The NASDAQ Global Market under the symbol "CYAD."

UBS Securities LLC and Piper Jaffray & Co. acted as joint book-running managers of the global offering and as representatives of the several underwriters, including Petercam NV/SA, Bryan, Garnier & Co., LifeSci Capital, LLC and Lake Street Capital Markets, LLC.

About Cooley LLP

High-growth and established companies, investors and investment banks focused on technology and life sciences partner with Cooley on transformative deals and high-stakes matters, where innovation meets the law.

Cooley has 850 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Kenneth Krisko Partner Reston, Boston
Marc Recht Partner Boston
Natasha Leskovsek Of Counsel Washington, DC
Bill Christiansen Partner Seattle
Phil Mitchell Partner New York
Giselle Rivers Partner Boston, New York
Div Gupta Partner New York
Richard Segal Partner Boston